


# Differential effect of inhaled β2-agonist on the characteristics of β1- and β2-adrenoreceptors in patients with cardiorespiratory pathology.

SMOLYAKOVA E.V.

National medical research center of cardiology

of the Ministry of healthcare of the Russian Federation


# Incidence of cardiovascular disease (CVD) and bronchial obstruction disease (BOD)




Arterial hypertension (AH) Chronic obstructive pulmonary disease(COPD Bronchial asthma (BA)

ЭССЕ 2014; Чазова И.Е. 2006; Кароли Н.А. и Ребров А.П. 2011; GOLD 2014

### **Medications**



# The effect of β-agonists and β-blockers on the characteristics of β-adrenergic receptors



Xiao RP et al. Subtypespecific a1- and badrenoceptor signaling in the heart TRENDS in Pharmacological Sciences Vol.27 No.6 June 2006

## The aim

 The aim of the study was to evaluate the changes of the characteristics of adrenoreceptors and spirometric parameters of patients with CVD (cardiovascular diseases) and BOD (bronchoobstructive diseases) after the initial administration of β2-agonist (formoterol) with and without previous therapy with selective β1-adrenoblocker (bisoprolol).

### Methods

➢Questionnaires: ACT, CAT, mMRC.

> Physical examination.

ECG in 12 leads, Holter ECG Monitoring, Ambulatory blood pressure monitoring.

Computer spirometry + bronchodilation test.

>Acute spirometric 4-hour test with selective beta1-blocker.


Modified radioligand analysis on T-lymphocytes of peripheral human blood.

### Modified radioligand analysis on Tlymphocytes of peripheral human blood

Activity binding of  $\beta$ -adrenoreceptors- this is a relative value that depends on:

- the number of receptors on the cell surface;
- the affinity of the receptor data;
- the availability of these receptors for a specific ligand

Nonspecifically ligand – [<sup>125</sup>I]-cyanopindolol Specifically  $\beta_1$  - ligand - CGP 20712A Specifically  $\beta_2$  - ligand - ICI 118551



Agapova O.Yu., Skoblov Yu. S., Zykov K.A.2016r


#### **Study design** 1 group **BIS 2,5 FORM 24** 15 **BIS 2,5** mg/day patients mg/day mg/day 30 patients with CVD and 120 min 60 min BOD BIS FORM (66.97±9.84 2 group years) FORM 24 15 **FORM 24 BIS 2,5** mg/day patients mg/day mg/day 60 min 120 min FORM BIS 9 day 1 day 1 visit 2 visit CVD - cardiovascular diseases.

BOD – bronchial obstructive diseases.


- evaluate the index of specific binding o beta-adrenergic receptors

BIS – bisoprolol. FORM – formoterol.


### Clinical efficacy and safety of selective β1-blocker and β2-agonist in CVD and BOD



### The number of patients with the greatest fall in FEV1% at different time periods



# The correlation between the parameters studied and the binding activity of $\beta$ 2-AR in patients with CVD and BOD in patients receiving:



### Conclusion

- With simultaneous administration of beta-agonists and beta-blockers, the order of prescription of drugs matters.
- A preliminary assignment of formoterol reduces the risk of bronchospastic effect of bisoprolol in patients with cardiorespiratory pathology that is accompanied by a decrease in specific binding of beta2-adrenergic receptors of peripheral blood lymphocytes.
- The phenomenon of decreasing of beta2-receptor's binding activity in patients treated with beta-blockers with the fall of FEV1 is worth attention for the conducting of further research. It needs to investigate whether the dynamics of beta-receptor's specific binding activity after the administration of beta-blockers and beta-agonists may be clinical biomarkers of future efficacy or possible side-effects of these drugs.

# Thank you your attention !